J Med Assoc Thai 2008; 91 (8):1189

Views: 1,254 | Downloads: 232 | Responses: 0

PDF XML Respond to this article Print Alert & updates Request permissions Email to a friend

Effect of Atorvastatin on LDL & hs-CRP in a Selected Thai Population
Boonbaichaiyapruck S Mail, Cheepudomwit S , Panjavenin P , Suthichaiyakul T , Moleelerkpoom W , Benjanuwatra T , Sukanandachai B , Buakhamsri A

Background: LDL and hs-CRP are risk factors for vascular events and can be modified by Statin.

To evaluate the baseline hs-CRP of a certain Thai population who would need Atorvastatin, to
evaluate the dose response of Atorvastatin toward LDL and hs-CRP level, and to evaluate the efficacy and
safety of different types of Atorvastatin.

Material and Method:
Subjects, who needed Statin therapy, were randomized to receive either 20 mg of
Berlin(B)-Atorvastatin(R) or Pfizer(P)-Atorvastatin(R). The cross over took place after 8 weeks of therapy and
continued for 16 weeks. Baseline blood tests were compared to 8 and 16 weeks. The effect of two brands of 20
mg Atorvastatin toward serum lipid, LFT, muscle enzyme and hs-CRP were compared.

Results: One hundred and ten subjects aged between 20-75 years enrolled in the present study. Fifty-four and
56 patients were randomized to group A and B. Baseline total cholesterol, LDL, HDL, and TG were 251, 174,
55, and 160 mg/dl respectively. There was a wide variation of baseline hs-CRP level. One hundred and seven
patients completed this 16 weeks study. Atorvastatin 20 mg lowered TC by 32%, LDL 44% and hs-CRP 10% at
16 weeks for the entire study (p < 0.003). The effect of either Atorvastatin the lipid profiles and hs-CRP were
different. There was no significant change in LFT or muscle enzyme.

Atorvastatin 20 mg has a dramatic effect on the lipid but moderate effect on CRP. The two different
types of Atorvastatin (group A and B) have similar effect on both safety and efficacy.

Atorvastatin, LDL, CRP

Download: PDF